Skip to content

Depression: all studies

Page 739 of 1,037: studies 7,381 to 7,390 of 10,363, newest first. Back to the depression overview

Research

Novel Perspective of Medicinal Mushroom Cultivations: A Review Case for ‘Magic’ Mushrooms

Agronomy December 15, 2022 Sarana Rose Sommano, Ratchuporn Suksathan, Thanarat Sombat et al. 16 citations

Fruiting bodies, mycelia, or spores in the form of extracts or powder of various medicinal mushrooms are used to prevent, treat, or cure a range of ailments and balance a healthy diet. Medicinal mushrooms are found in several genera of fungi and their fruit bodies, cultured mycelia, and cultured broth contains phytochemical constituents such as triterpenes, lectins, steroids, phenols,...

DOI: 10.3390/agronomy12123185 (opens in new tab) Psilocybin Mushroom Phytochemical Traditional medicine +4

Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD

The International Journal of Neuropsychopharmacology December 14, 2022 David Williamson, Ibrahim Turkoz, Ewa Wajs et al. 11 citations

BACKGROUND: "Dissociation" comprises distinct phenomena, some of which are associated with esketamine treatment and some may overlap with positive symptoms of psychosis. Relationships between dissociation and psychotic symptoms assessed by -clinician report vs conventional rating scales were investigated in a post hoc analysis of data from the initial treatment session in an -open-label,...

DOI: 10.1093/ijnp/pyac081 (opens in new tab) Dissociative Dissociation chemistry Rating scale Adverse effect +5

Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption

Journal of Psychopharmacology December 14, 2022 Emma Morton, Kimberly Sakai, Amir Ashtari et al. 75 citations

Background: Psilocybin, the primary psychoactive component of psychedelic ‘magic mushrooms’, may have potential for treating depressive symptoms, and consequent applications for bipolar disorder (BD). Knowledge of the risks and benefits of psilocybin in BD is limited to case studies. Aim: To support the design of clinical trials, we surveyed experiences of psilocybin use in people with BD....

DOI: 10.1177/02698811221131997 (opens in new tab) Psilocybin Bipolar disorder Mushroom poisoning Web survey +4

“A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use

PLoS One December 14, 2022 Meghan DellaCrosse, Mollie Pleet, Emma Morton et al. 28 citations

Objectives People with bipolar disorder (BD) spend more time depressed than manic/hypomanic, and depression is associated with greater impairments in psychosocial functioning and quality of life than mania/hypomania. Emerging evidence suggests psilocybin, the psychoactive compound in “magic mushrooms,” is a promising treatment for unipolar depression. Clinical trials of psilocybin therapy have...

DOI: 10.1371/journal.pone.0279073 (opens in new tab) Psilocybin Mental health Bipolar disorder Hypomania +5

Students experiences of an 8-week mindfulness-based intervention at a college of opportunity: a qualitative investigation of the mindfulness-based college program

BMC Public Health December 13, 2022 William Nardi, Nour Elshabassi, Jayson Spas et al.

Background Mindfulness-based programs have the potential to improve the well-being of undergraduate students by reducing anxiety, depression, and isolation in the wake of the COVID-19 pandemic. The aim of this qualitative study was to explore lived experiences of undergraduates in a mindfulness-based program at a “college of opportunity” that has high proportions of first-generation college...

The psychometric properties of the Vietnamese Version of the Five Facet Mindfulness Questionnaire

BMC Psychology December 12, 2022 Nguyễn Thị Minh Hằng, Hoang V. Nguyen, Thị Hồng Thái Bùi 7 citations

BACKGROUND: Although recent decades have witnessed a growing interest in mindfulness with the development of many mindfulness scales and their adaptation to different cultures, there has been no attempt at developing or adapting a mindfulness scale for Vietnamese people. To fill this gap and encourage the study of mindfulness in Vietnam, we adapted a 20-item short-form of the Five Facet...

A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects

medRxiv December 11, 2022 Hannah Hartland, Kimia Mahdavi, Luke A. Jelen et al. 22 citations preprint

Background: Ketamine may be effective in treating symptoms of anxiety, but the time profile of ketamine’s anxiolytic effect is ill-defined. This systematic review and meta-analysis investigated the anxiolytic effect of ketamine at different time points across a range of clinical settings. Methods: Electronic databases were searched to capture randomised control trials measuring the anxiolytic...

History of epilepsy increases risk of psychedelic‐induced seizures

The Brown University Psychopharmacology Update December 10, 2022

Classic psychedelic drugs such as psilocybin have been associated with reduced depressive symptoms when used as an adjunct to therapy, but concern remains over the potential for adverse events such as seizures when these drugs are used outside controlled clinical settings. A study used a survey of U.S. adults to examine the association between use of classic psychedelics and seizures. The...

Micro-dose, macro-impact: Leveraging psychedelics in frontline healthcare workers during the COVID-19 pandemic

Journal of Psychedelic Studies December 8, 2022 A. Atoian, Harry C. R. Bowles, Sarah Gerhke et al.

The COVID-19 pandemic exacerbated pre-existing high-levels of physician stress and burnout1. In order to help treat frontline colleagues who were diagnosed with acute stress disorder, we chose a non-psychedelic, ketamine micro-dose treatment strategy for symptom management.We provided care virtually, and all patients were prescribed sublingual ketamine once daily. Each patient was evaluated...

Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology

Neurosurgery December 8, 2022 Akanksha Sharma, Shanthi Gowrinathan, Karina Sergi et al. 13 citations

After a decades-long pause, psychedelics are again being intensely investigated for treating a wide range of neuropsychiatric ailments including depression, anxiety, addiction, post-traumatic stress disorder, anorexia, and chronic pain syndromes. The classic serotonergic psychedelics psilocybin and lysergic acid diethylamide and nonclassic psychedelics 3,4-methylenedioxymethamphetamine and...